Exhibiting at VIV Asia 2025

General Life Biotechnology Co., Ltd., headquartered in New Taipei City, Taiwan, is a technology-driven medical diagnostics company specializing in the development and manufacturing of point-of-care testing (POCT) systems. With a focus on human and veterinary health monitoring, the company is known for its innovation in multi-parameter diagnostic devices under the brands BeneCheck and SANcheck. Established to address the growing global need for accessible and portable diagnostic solutions, General Life Biotechnology has evolved into a trusted supplier of reliable, user-friendly, and clinically validated testing devices.

Core Business and Offerings

General Life Biotechnology designs, manufactures, and exports a full range of diagnostic monitoring systems that support chronic disease management, health screening, and veterinary care. The company’s product portfolio includes:

Multi-Function Monitoring Systems (Human Health)

• BeneCheck BK6-12M
  A 3-in-1 monitoring system for blood glucose (GLU), cholesterol (CHOL), and uric acid (UA) — ideal for users with comorbid conditions.

• BeneCheck PLUS
  Combines GLU, CHOL, UA, and hemoglobin (Hb) in a single compact device. Used in clinical settings and home healthcare.

• BeneCheck BK6-20M
  An upgraded version offering faster results and memory storage of up to 1000 readings across multiple parameters.

Single Function Monitoring Systems

• Premium GLU Monitoring System
  Fast and accurate glucose measurement with enhanced sensor strips and ISO compliance.

• Premium CHOL Monitoring System
  Allows easy home monitoring of cholesterol levels with results comparable to clinical labs.

• Premium UA Monitoring System
  Designed for patients managing hyperuricemia or gout.

• Premium Hb Monitoring System
  Hemoglobin test with results in 15 seconds, enabling anemia tracking.

Veterinary Diagnostic Devices

• SANcheck ABEL Vet GK Monitoring System
  Specially designed for measuring glucose and ketone levels in dogs and cats.

• SANcheck SweePaw
  A blood glucose monitoring system tailored for small pets, with species-specific calibration for accurate results.

Specialization and Core USP

General Life Biotechnology’s unique position in the diagnostic device market is defined by its ability to offer multi-parameter testing in a single device, drastically reducing testing time and cost. The company’s core innovations include:

• Integrated strip technology for combined assays
• Auto-coding features to eliminate manual calibration errors
• Portable, battery-powered devices suitable for remote and home use
• Real-time data storage and USB/Bluetooth connectivity for digital health tracking

Their veterinary monitoring systems also address a specialized niche, offering clinical-grade accuracy in non-human applications.

Financials and Market Performance

Although the company does not publicly disclose its revenue, export trade records and global distributor listings suggest that General Life Biotechnology has an active market presence in over 35 countries, particularly in:

• Southeast Asia
• Latin America
• Eastern Europe
• Middle East

Annual estimated revenue is believed to be in the range of USD 5–8 million, with 40% derived from OEM/ODM partnerships and 60% from proprietary brand exports and domestic sales.

International Shipments and Market Reach

Trade data and product listings confirm distribution channels across:

• Philippines, Thailand, and Vietnam (public health sector and pharmacies)
• Brazil and Mexico (clinical chains and home health distributors)
• Poland, Turkey, and UAE (medical device retailers)
• Taiwan and China (direct-to-consumer via e-commerce and clinics)

The company participates in global exhibitions such as MEDICA (Germany) and CMEF (China), strengthening its brand among healthcare procurement professionals.

Target Market

General Life Biotechnology serves a wide audience:

• Patients with chronic conditions (diabetes, gout, anemia)
• General practitioners and clinics
• Pharmacies and healthcare retailers
• Veterinary clinics and pet owners
• Government and NGO-led public health programs

Capabilities

• In-house R&D Team: With expertise in biosensor technology, microelectronics, and clinical validation
• Regulatory Experience: Products certified with CE, ISO 13485, and many with FDA (510k) clearances
• OEM/ODM Services: Full-scale design, branding, and supply chain solutions for partners worldwide
• Production Facility: High-throughput assembly line capable of manufacturing over 500,000 devices annually

Certifications and Compliance

• ISO 13485:2016 Certified (Medical Devices – Quality Management System)
• CE marking for EU distribution
• Taiwan FDA approval for domestic use
• Complies with IEC 60601 standards for electrical safety
• Ongoing clinical validation for new test parameters

Customer Testimonials

“The BeneCheck PLUS system allows our clinic to test glucose, cholesterol, and hemoglobin from a single device. It’s helped us speed up diagnosis and reduce patient wait times.”
— Clinic Owner, Philippines

“The SANcheck vet device is extremely easy to use. Our clients are impressed with the accuracy and portability for their diabetic pets.”
— Veterinarian, Malaysia

Achievements

• Export presence in 35+ countries
• Chosen POCT supplier for NGO-led rural healthcare initiatives in Southeast Asia
• Launched one of the world’s first 4-in-1 diagnostic devices
• Patent portfolio includes integrated multi-assay strip systems
• Named among Taiwan’s Top 100 Innovative Health Companies in 2022

General Life Biotechnology Co., Ltd. continues to redefine decentralized diagnostics with its mission to deliver affordable, reliable, and multifunctional health monitoring systems to both human and animal care markets across the globe.